Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Early trial results of heart drug suggests Novartis has a winner on its hands

1/04/2014 by

W1siziisijiwmtqvmtavmjgvmtuvndyvndavmtc0l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0


Novartis has started the week on a high note, with the pharmaceutical company announcing its plans to terminate a drug trial ahead of schedule. The decision was made on the unanimous recommendation of an independent committee, with the company now seeking approval on the basis of the drug’s positive results thus far.

The drug, LCZ696, was recommended after early results showed that patients trialling it lived longer – and without hospitalization – than patients taking enalapril. Designed to treat heart failure, Novartis is going to present the findings and the case for approval at an upcoming meeting with various global health authorities. Milton Packer, co-Principal investigator of trial, confirmed that the evidence in LCZ696′s favor was indeed strong enough to warrant stopping the trial. “The stopping rule was not on the primary endpoint, it was on cardiovascular death,” he said to Forbes’ Larry Husten. “It was a stopping rule that required a very high level of statistical significance for early termination.”

The news comes in contrast to last week’s response to Serelaxin, another Novartis drug that the U.S. Food and Drug Administration (FDA) turned down for approval. Also intended to treat heart disease, Serelaxin did not present a strong enough case, with minimal evidence to support its claims. Earlier this year, a European advisory committee cast similar judgement, limiting Serelaxin’s future in cardiac medicine.

This article has been extracted from http://www.techtimes.com, please click on this link to read the article in full http://www.techtimes.com/articles/5031/20140331/early-trial-results-of-heart-drug-suggests-novartis-has-a-winner-on-its-hands.htm

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

For more information please visit www.montash.com

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdevmjavmtavntyvmtkvnzgzl0nsts5qcgcixsxbinailcj0ahvtyiisijm4mhgxmdajil1d

Salesforce moves into Seattle with new engine...

2017-01-20 10:00:00 +0000

Salesforce, a world leader in customer relationship management (CRM) solutions, has revealed that it is to open an innovation and engineering hub in Seattle. In order to increase the firm’s presence in the city, Salesforce Co-Founder Parker Harris said that the office located in Bellevue’s Nine Two Nine Office Tower will focus on its artificial intelligence (AI) initiatives. One reason for the move is so that the firm can access a new pool of talent. Ta...

W1siziisijiwmtcvmdevmtgvmdkvmtqvmzmvmzk5l0vsuc5qcgcixsxbinailcj0ahvtyiisijm4mhgxmdajil1d

Sage bolsters X3 business ERP solution

2017-01-18 09:00:00 +0000

Sage, one of the global leaders in enterprise resource planning (ERP) solutions, has revealed that it has signed up a trio of new clients to its X3 business solution. With the Salesforce.com partner wanting to be able to show its ability to host larger clients, the firm revealed that BrightBridge, Atlas Cloud and CLOUT are all now utilising the new and emerging X3 ERP platform. Sage Vice President of UK Enterprise David Watts talked about the latest agr...